[1] Llovet JM,Burroughs A,Bruix J.Hepatocellular carcinoma. Lancet,2003,362:1907. [2] Parkin DM,Bray F,Ferlay J,et al.Global cancer statistics,2002. CA Cancer J Clin,2005,55:74. [3] Chen CJ,Yu MW,Liaw YF.Epidemiological characteristics and risk factors of hepatocellular carcinoma. J Gastroenterol Hepatol,1997,12:S294. [4] Thorgeirsson SS,Grisham JW.Molecular pathogenesis of human hepatocellular carcinoma. Nat Genet,2002,31:339. [5] Bruix J,Boix L,Sala M,et al.Focus on hepatocellular carcinoma. Cancer Cell,2004,5:215. [6] Laurent-Puig P,Legoix P,Bluteau O,et al.Genetic alterations associated with hepatocellular carcinomas define distinct pathways of hepatocarcinogenesis. Gastroenterology,2001,120:1763. [7] Wang XM,Yang LY,Guo L,et al.p53-induced RINGH2 protein,a novel marker for poor survival in hepatocellular carcinoma after hepatic resection. Cancer,2009,115:4554. [8] Lau WY,Lai EC.Hepatocellular carcinoma: current management and recent advances. Hepatobiliary Pancreat Dis Int,2008,7:237. [9] Manser E,Leung T,Salihuddin H,et al.A brain serine/threonine protein kinase activated by Cdc42 and Rac1. Nature,1994,367:40. [10] Knaus UG,Morris S,Dong HJ,et al.Regulation of human leukocyte p21-activated kinases through G proteinecoupled receptors. Science,1995,269:221. [11] Martin GA,Bollag G,McCormick F,et al. A novel serine kinase activated by rac1/CDC42Hs-dependent autophosphorylation is related to PAK65 and STE20. EMBO J,1995,14:1970. [12] Bagrodia S,Taylor SJ,Jordon KA,et al.A novel regulator of p21-activated kinases. J Biol Chem,1998,273:23633. [13] Kumar R,Vadlamudi RK.Emerging functions of p21-activated kinases in human cancer cells. J Cell Physiol,2002,193:133. [14] Bokoch GM.Biology of the p21-activated kinases. Annu Rev Biochem,2003,72:743. [15] Hofmann C,Shepelev M,Chernoff J.The genetics of Pak. J Cell Sci,2004,117:4343. [16] Kumar R,Gururaj AE,Barnes CJ. p21-activated kinases in cancer. Nat Rev Cancer,2006,6:459. [17] Wells CM,Jones GE.The emerging importance of group II PAKs. Biochem J,2010,425:465. [18] Jaffer ZM,Chernoff J. p21-activated kinases:three more join the Pak. Int J Biochem Cell Biol,2002,34:713. [19] Zhao ZS,Manser E.PAK and other Rho-associated kinaseseeffectors with surprisingly diverse mechanisms of regulation. Biochem J,2005,386:201. [20] Arias-Romero LE,Chernoff J.A tale of two Paks. Biol Cell,2008,100:97. [21] Carter JH,Douglass LE,Deddens JA,et al.Pak-1 expression increases with progression of colorectal carcinomas to metastasis. Clin Cancer Res,2004,10:3448. [22] Bekri S,Adelaide J,Merscher S,et al.Detailed map of a region commonly amplified at 11q13>q14 in human breast carcinoma. Cytogenet Cell Genet,1997,79:125. [23] Siu MK,Wong ES,Chan HY,et al.Differential expression and phosphorylation of Pak1 and Pak2 in ovarian cancer:effects on prognosis and cell invasion. Int J Cancer,2010,127:21. [24] Ching YP,Leong VY,Lee MF,et al.P21-activated protein kinase is overexpressed in hepatocellular carcinoma and enhances cancer metastasis involving c-Jun NH2-terminal kinase activation and paxillin phosphorylation. Cancer Res,2007,67:3601. [25] Vadlamudi RK,Adam L,Wang RA,et al.Regulatable expression of p21-activated kinase-1 promotes anchorageindependent growth and abnormal organization of mitotic spindles in human epithelial breast cancer cells. J Biol Chem,2000,275:36238. [26] Adam L,Vadlamudi R,Mandal M,et al.Regulation of microfilament reorganization and invasiveness of breast cancer cells by kinase dead p21-activated kinase-1. J Biol Chem,2000,275:12041. [27] Engelman JA,Luo J,Cantley LC.The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nat Rev Genet,2006,7(8):606-619. [28] Bellacosa A,Kumar CC,Cristofano AD,et al.Activation of AKT kinases in cancer:implications for therapeutic targeting. Adv Cancer Res,2005,94:29-86. [29] Iyer SC,Gopal A,Halagowder D.Myricetin induces apoptosis by inhibiting P21 activated kinase 1(PAK1) signaling cascade in hepatocellular carcinoma. Mol Cell Biochem,2015,407(1-2):223-237. [30] Li YY,Li J,Chen L.Axl as a downstream effector of TGF-β1 via PI3K/Akt-PAK1 signaling pathway promotes tumor invasion and chemoresistance in breast carcinoma. Tumour Biol,2014,35(4):3809-3817. [31] Huynh N,Kevin HL,Baldwin GS,et al.P21-activated kinase 1 stimulates colon cancer cell growth and migration/invasion via ERK-and AKT-dependent pathways. Biochim Biophys Acta,2010,1803:1106-1113. [32] Balmanno K,Chell SD,Gillings AS,et al.Intrinsic resistance to the MEK1/2 inhibitorAZD6244 (ARRY-142886) is associated with weak ERK1/2 signalling and/or strong PI3K signalling in colorectal cancer cell lines. Int J Cancer,2009,125:2332-2341. |